Nanospectra

Houston, United States Founded: 2002 • Age: 24 yrs
Nanoparticle-based therapies for solid tumor treatment are developed.

About Nanospectra

Nanospectra is a Technology company based in Houston (United States) founded in 2002. Nanoparticle-based therapies for solid tumor treatment are developed. It operates in the Technology and Healthcare sectors. Nanospectra has raised $24.52 million across 21 funding rounds from investors including HHS, National Cancer Institute and Sirtex. The company has 9 employees. Nanospectra offers products and services including AuroLase Therapy and AuroShells. Its focus areas include Life Sciences, Oncology, Medical Devices and Therapies. Its legal entity is Nanospectra Biosciences, Inc. Its competitors include RefleXion, Sirnaomics and Liquidia; 3 of its 3 listed competitors have raised funding.

Company details

Nanospectra was established in 2002 in Houston, United States, within the biotechnology sector. Particle-based therapies for the thermal ablation of solid tumors, including those in prostate, brain, and breast, are commercialized. AuroLase Therapy, a medical device designed for precise tumor destruction, is offered to address various solid malignancies through selective nanoparticle application. Operations focus on advancing these treatments for clinical use.

  • Headquarters Houston, United States
  • Employees 9
  • Sectors
    Technology
    Healthcare
  • Website nanospectra.com
  • Social LinkedIn X
  • Legal Name Nanospectra Biosciences, Inc.
Key Metrics
  • Total Equity Funding
    $24.52M (USD)

    in 21 rounds

  • Latest Funding Round
    $6.07M (USD), Series B

    Mar 2023

  • Investors
    HHS

    & 3 more

  • Employee Count
    9

Products & Services of Nanospectra

Nanospectra offers a comprehensive portfolio of products and services, including AuroLase Therapy and AuroShells.

AuroLase Therapy
Thermal Ablation Therapy

Uses nanoparticles to selectively destroy tumors via heat.

AuroShells
Nanoparticles

Gold particles that convert light into heat for medical ablation.

Funding Insights of Nanospectra

Nanospectra has successfully raised a total of $24.52M across 21 strategic funding rounds. The most recent funding activity was a Series B round of $6.07 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $24.52M
  • Total Rounds 21
  • Last Round Series B β€” $6.07M
  • First Round $232,800

    (Aug 2003)

  • Investors Count 4

Latest 10 of 21 funding rounds of Nanospectra with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Mar 2023$6.07MSeries B––
–
Aug 2020$8.61MSeries B–Sirtex Medical
–
Feb 2017$2.03MSeries A––
–
Dec 2015$945,995Seed––
–
Aug 2014$800,000Seed––
–
Jun 2013$525,000Seed––
–
Jun 2013$2.42MSeed––
–
Nov 2010$872,973Seed––
–
Sep 2010$113,665Grant––
Sep 2010$113,665Grant––
Valuation history

4 investors in total: 4 institutional.

Investors in Nanospectra

Nanospectra has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include HHS, National Cancer Institute and Sirtex.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Radiation therapy for cancer treatment is developed and provided.
1991sirtex.comSydney, Australia
Public health and human services are overseen by HHS.
1953hhs.gov
Cancer research is conducted and supported by the institute.
cancer.govBethesda, United States
Research and information on aging are provided by this institute.
nia.nih.govBethesda, United States
Premium access

Investor details for Nanospectra

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Nanospectra

10 people are tracked at Nanospectra (4 in leadership, 6 in board & advisors); the tracked headcount is 9.

NameRoleGroup
David Jorden
CEO & DirectorLeadership
Glenn P. Goodrich
COO & VP, Process Development & ChemistryLeadership
Michael Brawer
Chief Medical OfficerLeadership
Jon Schwartz
Director, Clinical ResearchLeadership
Brian Pryor
DirectorBoard & advisors
Patrick W. Pace
ChairmanBoard & advisors
Brad Nyberg
DirectorBoard & advisors
L. Blair Shamel
DirectorBoard & advisors
Naomi Halas
AdvisorBoard & advisors
Jennifer West
AdvisorBoard & advisors
Premium access

Complete people profiles for Nanospectra

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Nanospectra

3 dated milestones of Nanospectra across 21 years, from founding to its latest funding, stage changes and deals.

  1. Founded Nanospectra is founded.
  2. Funding First funding round of $233K.
  3. Funding Latest funding round, Series B, of $6.1M.

Competitors of Nanospectra

Nanospectra has 3 listed competitors in our database, 3 of them funded. They include RefleXion, Sirnaomics and Liquidia.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
reflexion.com2009Hayward, United States$553.91M257
Biology-guided radiotherapy systems are provided for cancer treatment.
sirnaomics.com2007Gaithersburg, United States$267M88
RNA-based therapeutics for cancer and fibrosis are developed.
liquidia.com2004United States$75.3M63
Engineered particles & films for life and material sciences applications
Premium access

Detailed competitors of Nanospectra

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Nanotechnology

3 companies that operate in the same segment as Nanospectra (Nanotechnology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of technologies for analysis of genetic variation and function
1993San Diego, California, United StatesUSD 28 MUSD 34.92 M9,630
RNA interference-based therapeutics are developed for multiple disorders.
2002Cambridge, Massachusetts, United StatesUSD 17 MUSD 3.71 B2,230
Aerogel-based thermal insulation solutions are provided for energy conservation.
2001United StatesUSD 198.35 MUSD 271.1 M554
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Nanospectra

Premium access

Complete news archive for Nanospectra

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nanospectra

Nanospectra was founded in 2002 and raised its 1st funding round 1 year after it was founded.

Nanospectra is headquartered in Houston, United States. It is registered at Houston, Texas, United States.

Nanospectra is a funded company, having raised a total of $24.52M across 21 funding rounds to date. The company's 1st funding round was a Grant of $113.67K, raised on Aug 2003.

Nanospectra has 9 employees.

Nanospectra was established in 2002 in Houston, United States, within the biotechnology sector. Particle-based therapies for the thermal ablation of solid tumors, including those in prostate, brain, and breast, are commercialized. AuroLase Therapy, a medical device designed for precise tumor destruction, is offered to address various solid malignancies through selective nanoparticle application. Operations focus on advancing these treatments for clinical use.

Nanospectra's top competitors include RefleXion, Sirnaomics and Liquidia.

Nanospectra offers AuroLase Therapy and AuroShells.

Nanospectra has 4 investors. Key investors include HHS, National Cancer Institute, Sirtex, and National Institute on Aging.

Nanospectra operates through Nanospectra Biosciences, Inc..

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available